Title: Role of Efonidipine in CKD Patients: A Study In North Bihar
Authors: Dr U. C. Jha, Dr Ashish Narayan
DOI: https://dx.doi.org/10.18535/jmscr/v7i2.56
Abstract
The role of efonidipine, a calcium channel blocker in reducing the progression of chronic renal disease is well established by various studies. It also imparts beneficial effects in cardiovascular disease by reducing synthesis and secretion of aldosterone, it prevents hypertrophy and remodelling of cardiac myocytes. There is decrease in 24 hour urinary protein as efonidipine reduces glomerular capillary pressure. And overall there is improvement in GFR too. The aim of the study is to find the role of efonidipine in CKD patients.
Methods: CKD patients (age >25 years, both gender) attending outdoor clinic and indoor CKD patients of Medicine department Darbhanga Medical College were selected by simple random method and advised efonidipine 40mg once daily. The statistical significance of improvement in proteinuria and GFR was measured.
Result: There was improvement in proteinuria in 52% patients taking efonidipine 40mg once daily. The GFR was increased in 54% patients taking drug.
Out of 50 patients 29 were male and 21 were females. There was substantial decrease in 24 hour urinary protein in 26 patients out of 50 at the end of 6 months period. GFR also improved in 27 patients out of 50 at the end of study period.
Conclusion: Our 24 weeks study period in CKD patients taking efonidipine a novel dihydropyridine calcium antagonist showed its beneficial effects. The outcome was measured by 24 hour urinary protein excretion and GFR. The beneficial effect on proteinuria was particularly apparent in patients with proteinuria 1 g/day. These effects of efonidipine would appear to make the drug more advantageous than other CCBs in terms of slowing the progression of renal dysfunction and preventing cardiovascular tissue and organ injuries in patients with hypertension and chronic kidney disease.
References
- Koichi Hayashi, Hiroo Kumagai, and Takao Saruta Effect of Efonidipine and ACE Inhibitors on Proteinuria in Human Hypertension With Renal Impairment AJH 2003; 16:116–122
- Toshihiko ISHIMITSU1), Tomoko KAMEDA1), Akira AKASHIBA1), Toshiaki TAKAHASHI1), Satoshi OHTA1), Masayoshi YOSHII1), Junichi MINAMI1), Hidehiko ONO1), Atsushi NUMABE1), and Hiroaki MATSUOKA1) Efonidipine Reduces Proteinuria and Plasma Aldosterone in Patients with Chronic Glomerulonephritis.
- Mitsuyuki Shimizu, MD, Kazuhiko Ogawa, MD, Hideki Sasaki, MD, Yoshiki Uehara, MD, Yumi Otsuka, MD, Hiroyuki Okumura, MD, Masafumi Kusaka, MD, Toshio Hasuda, MD, Taku Yamada, MD, and Seibu Mochizuki, MD Effects of Efonidipine, an L- and T-Type Dual Calcium Channel Blocker, on Heart Rate and Blood Pressure in Patients with Mild To severe Hypertension: An Uncontrolled, Open-Label Pilot Study.
- Toshinari TANAKA1), Takayoshi TSUTAMOTO1), Hiroshi SAKAI1), Masanori FUJII1), Takashi YAMAMOTO1), and Minoru HORIE1) Comparison of the Effects of Efonidipine and Amlodipine on Aldosterone in Patients with Hypertension.
- Schulman NB, Ford CE, Hall WD, Blaufox MD, Simon D, Langford HG, Schneider KA: Prognostic value of serum creatinine and effect of treatment of hypertension on renal function: Results from the hypertension detection and follow-up program. Hypertension 1989;13(Suppl 1):I-80–I-93.
- Lewis EJ, Hunsicker LG, Bain RP, Rohde RD, for the Collaborative Study Group: The effect of angiotensin converting enzyme inhibition on diabetic nephro-pathy. N Engl J Med 1993;329: 1456–1462.
- Tanaka H, Shigenobu K: Pathophysiological significance of T-type Ca2+ channels: T-type Ca2+ channels and drug development. J Pharmacol Sci 2005; 99: 214–220.
- Sato A, Hayashi K, Saruta T: Antiproteinuric effects of mineralocorticoid receptor blockade in patients with chronic renal disease. Am J Hypertens 2005; 18: 44–49.
- Cockcroft DW, Gault MH: Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41.
- Hunsicker LG, Atkins RC, Lewis JB, et al: Impact of irbesartan, blood pressure control, and proteinuria on renal outcomes in the Irbesartan Diabetic Nephropathy Trial. Kidney Int Suppl 2004; 92: S99–S101.